Completed PHASE4 INTERVENTIONAL 2-arm NCT01200056

Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment (VENUS)

A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound

Sponsor: Pfizer

Conditions Coronary Disease Hydroxymethylglutaryl-CoA Reductase Inhibitors Ultrasonography, Interventional

Interventions Atorvastatin 10mg versus 40mg.

Updated 5 times since 2017 Last updated: Feb 27, 2013 Started: Aug 31, 2007 Primary completion: Nov 30, 2009 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01200056, this PHASE4 trial focuses on Coronary Disease and Hydroxymethylglutaryl-CoA Reductase Inhibitors and remains completed. Sponsored by Pfizer, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Prof. Stephen Lee
Queen Mary Hospital, Hong Kong

Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong SAR, China